RA
Royce & Associates Portfolio holdings
AUM
$9.74B
1-Year Return
15.99%
This Quarter Return
+7.64%
1 Year Return
+15.99%
3 Year Return
+81.23%
5 Year Return
+192.6%
10 Year Return
+438.14%
AUM
$11.2B
AUM Growth
+$377M
(+3.5%)
Cap. Flow
-$196M
Cap. Flow
% of AUM
-1.75%
Top 10 Holdings %
Top 10 Hldgs %
9.83%
Holding
944
New
84
Increased
322
Reduced
334
Closed
72
Top Buys
| 1 |
Haemonetics
HAE
|
$25.6M |
| 2 |
Shutterstock
SSTK
|
$23.7M |
| 3 |
BELFB
Bel Fuse Class B
BELFB
|
$23.3M |
| 4 |
Exponent
EXPO
|
$17.5M |
| 5 |
Vestis
VSTS
|
$17.4M |
Top Sells
| 1 |
HAYN
Haynes International, Inc.
HAYN
|
$30.6M |
| 2 |
MKS Inc. Common Stock
MKSI
|
$26.6M |
| 3 |
Fair Isaac
FICO
|
$25.4M |
| 4 |
Kadant
KAI
|
$21M |
| 5 |
LCI Industries
LCII
|
$20.6M |
Sector Composition
| 1 | Industrials | 27.18% |
| 2 | Technology | 19.17% |
| 3 | Financials | 13.41% |
| 4 | Consumer Discretionary | 12.61% |
| 5 | Materials | 7.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
801
AMC Networks
AMCX
$328M
| $420K | ﹤0.01% |
34,620
-2,875
| -8% | -$34.9K |
|
802
Alta Equipment Group
ALTG
$275M
| $416K | ﹤0.01% |
+32,103
| New | +$416K |
|
803
Lifecore Biomedical
LFCR
$282M
| $401K | ﹤0.01% |
75,610
| – | – |
|
|
TBNK
804
DELISTED
Territorial Bancorp Inc.
TBNK
| $400K | ﹤0.01% |
49,611
-33,351
| -40% | -$269K |
|
805
Actinium Pharmaceuticals
ATNM
$49.3M
| $392K | ﹤0.01% |
50,000
| – | – |
|
806
Pathward Financial
CASH
$1.74B
| $382K | ﹤0.01% |
+7,575
| New | +$382K |
|
807
Robert Half
RHI
$3.77B
| $382K | ﹤0.01% |
4,822
| – | – |
|
808
ScottsMiracle-Gro
SMG
$3.64B
| $373K | ﹤0.01% |
5,000
| – | – |
|
809
Travere Therapeutics
TVTX
$1.93B
| $367K | ﹤0.01% |
47,573
+5,932
| +14% | +$45.7K |
|
810
Liquidia Corp
LQDA
$2.48B
| $354K | ﹤0.01% |
+24,000
| New | +$354K |
|
|
ENV
811
DELISTED
ENVESTNET, INC.
ENV
| $347K | ﹤0.01% |
6,000
| – | – |
|
812
MaxCyte
MXCT
$150M
| $341K | ﹤0.01% |
81,428
-245,910
| -75% | -$1.03M |
|
813
Insulet
PODD
$24.5B
| $340K | ﹤0.01% |
1,981
-36,813
| -95% | -$6.31M |
|
814
Prime Medicine
PRME
$663M
| $323K | ﹤0.01% |
46,214
+6,377
| +16% | +$44.6K |
|
815
Fate Therapeutics
FATE
$116M
| $319K | ﹤0.01% |
43,399
-63,919
| -60% | -$469K |
|
816
FTAI Infrastructure
FIP
$481M
| $316K | ﹤0.01% |
50,269
-38,863
| -44% | -$244K |
|
817
MarketAxess Holdings
MKTX
$7.01B
| $312K | ﹤0.01% |
1,423
| – | – |
|
818
Outfront Media
OUT
$3.05B
| $301K | ﹤0.01% |
18,186
| – | – |
|
819
Kymera Therapeutics
KYMR
$3.11B
| $284K | ﹤0.01% |
7,076
-8,928
| -56% | -$359K |
|
820
Telus
TU
$25.3B
| $261K | ﹤0.01% |
16,311
| – | – |
|
821
Castle Biosciences
CSTL
$683M
| $246K | ﹤0.01% |
11,125
-20,517
| -65% | -$454K |
|
822
Werewolf Therapeutics
HOWL
$61.7M
| $242K | ﹤0.01% |
+37,321
| New | +$242K |
|
823
GeoPark
GPRK
$326M
| $241K | ﹤0.01% |
25,100
-44,118
| -64% | -$424K |
|
824
Rayonier Advanced Materials
RYAM
$397M
| $239K | ﹤0.01% |
50,000
-35,855
| -42% | -$171K |
|
825
Taylor Devices
TAYD
$151M
| $235K | ﹤0.01% |
+4,726
| New | +$235K |
|